December 12, 2011 writer

TSO3 : ORIGINAL CUSTOMERS UPGRADE TO NEW 3M™ OPTREOZ™ 125-Z STERILIZER

Quebec City, Canada, December 12, 2011 – TSO3 Inc. (“TSO3” or the “Company”) (TSX: TOS) an innovator in low temperature sterile reprocessing solutions for medical devices in healthcare settings, today reported 80% of its initial Canadian customers (125L Ozone Sterilizer users) have agreed to upgrade to the new 3M™ Optreoz™ 125-Z sterilizer by the end of January 2012. These additional 3M sterilizers will be adding to the already installed and revenue generating unit base.

The upgrade is a special promotion offered by TSO3 to its initial customers. It offers a trade-in value when a 125L Ozone Sterilizer is replaced by a 3M™ Optreoz™ 125-Z. At this time, the offer has been extended to Canadian customers only, representing a dozen sterilizers.  TSO3 plans to offer a similar upgrade opportunity to American customers, once the United States commercial clearance is received, representing a potential of some 20 additional sterilizers.

“Customers see the benefit of using their existing sterilizer 125L Ozone Sterilizer to help fund the purchase of a 3M™ Optreoz™ 125-Z”, said R.M. (Ric) Rumble, CEO of TSO3. “We are thrilled by the response of these long term customers and we continue to receive highly satisfied responses on installation of 3M sterilizers”, he concluded.

About TSO3

TSO3 enables better health care through the development of innovative, low-temperature medical device sterilization systems and offers these solutions through licensing agreements to reputable channel partners for global commercial reach.

The TSO3 sterile reprocessing solutions answer the global and growing need for economical and fast turnaround of a wide range of medical instruments. These solutions address cutting-edge, high-demand devices – such as flexible endoscopes – and support the development of increasingly sophisticated medical devices and techniques.

At TSO3 ‘s core, is its ability to conduct rapid research, development and prototyping  as well as validating biocompatibility and functionality of innovative medical reprocessing systems. TSO3 maintains a rigorous quality system as well as in-house expertise for regulatory submissions.

For more information about TSO3, visit the Corporation’s Web site at www.tso3.com

Caution regarding forward-looking statements

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.

The Toronto Stock Exchange has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

-30-

Back to Posts